Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4799440
Max Phase: Preclinical
Molecular Formula: C49H73N5O17S
Molecular Weight: 1036.21
Molecule Type: Unknown
Associated Items:
ID: ALA4799440
Max Phase: Preclinical
Molecular Formula: C49H73N5O17S
Molecular Weight: 1036.21
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCCC(=O)NCCC(=O)N[C@@H](CS(=O)(=O)O)C(=O)N(C)[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)O)Cc2ccc(O)c(c2)-c2cc1cc(O)c2O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O
Standard InChI: InChI=1S/C49H73N5O17S/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-38(57)50-22-21-39(58)52-35(27-72(67,68)69)47(64)54(4)40-31-25-33(44(37(56)26-31)71-49-43(61)42(60)41(59)29(3)70-49)32-23-30(19-20-36(32)55)24-34(48(65)66)53-45(62)28(2)51-46(40)63/h19-20,23,25-26,28-29,34-35,40-43,49,55-56,59-61H,5-18,21-22,24,27H2,1-4H3,(H,50,57)(H,51,63)(H,52,58)(H,53,62)(H,65,66)(H,67,68,69)/t28-,29-,34-,35-,40-,41-,42+,43+,49-/m0/s1
Standard InChI Key: MLNOYAAWUBVMKP-KJOBYZJESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1036.21 | Molecular Weight (Monoisotopic): 1035.4722 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Tan YX,Peters DS,Walsh SI,Holcomb M,Santos-Martins D,Forli S,Romesberg FE. (2020) Initial Analysis of the Arylomycin D Antibiotics., 83 (7): [PMID:32614583] [10.1021/acs.jnatprod.9b01174] |
Source(1):